Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
2023 · The Lancet · 220 citations
https://doi.org/10.1016/s0140-6736(23)00222-2
D
Dalia Wajsbrot
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
78
Papers
1.7K
Citations
19
h-index
27
i10-index
Dalia Wajsbrot is an academic researcher from Pfizer (United States). The author has contributed to research in topics: Hair Growth and Disorders & Treatment of Major Depression & Wound Healing and Treatments. The author has an h-index of 19, co-authored 67 publications.
Papers by this author
worksDesvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder
2017 · Journal of Child and Adolescent Psychopharmacology · 43 citations
https://doi.org/10.1089/cap.2017.0100
Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder
2017 · Journal of Child and Adolescent Psychopharmacology · 33 citations
https://doi.org/10.1089/cap.2017.0099
Efficacy of venlafaxine extended release in major depressive disorder patients
2019 · International Clinical Psychopharmacology · 21 citations
https://doi.org/10.1097/yic.0000000000000256
A meta-analysis of the efficacy of venlafaxine extended release 75–225 mg/day for the treatment of major depressive disorder
2016 · Current Medical Research and Opinion · 14 citations
https://doi.org/10.1080/03007995.2016.1255185
Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis
2020 · Journal of Psychiatric Research · 13 citations
https://doi.org/10.1016/j.jpsychires.2020.06.011
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat